孕期类风湿关节炎治疗中的临床药代动力学
Clinical pharmacokinetics in the treatment of rheumatoid arthritis in pregnancy.
作者信息
Witter F R
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
Clin Pharmacokinet. 1993 Dec;25(6):444-9. doi: 10.2165/00003088-199325060-00004.
Rheumatoid arthritis is a relatively common problem in women of reproductive age. Pregnancy may affect all aspects of the pharmacokinetics of the drugs used in its treatment. The effects of pregnancy on the pharmacokinetics of drugs are, for the most part, not clinically significant. The pharmacokinetics of placental transfer and fetal safety have been specified for many drugs. Drugs used in rheumatoid arthritis can be classified into 3 classes: those with the greatest safety for the fetus, those that are unsafe for the fetus, and those for which there are insufficient data to determine the risk to the fetus.
类风湿关节炎在育龄女性中是一个相对常见的问题。怀孕可能会影响用于治疗该疾病的药物的药代动力学的各个方面。在大多数情况下，怀孕对药物药代动力学的影响在临床上并不显著。许多药物的胎盘转运药代动力学和胎儿安全性已经明确。用于类风湿关节炎的药物可分为三类：对胎儿安全性最高的药物、对胎儿不安全的药物以及尚无足够数据确定对胎儿风险的药物。
Zotero 插件